February 13, 2024 - by Catie Corcoran

Adverum Demonstrates “Sustained Disease Control” in Phase 2 Trial for Macular Degeneration

13 February 2024

New York, February 13, 2024 - PRISM MarketView - PRISM MediaWire - Adverum Biotechnologies (Nasdaq: ADVM) has reported positive preliminary safety and efficacy data from a Phase 2 trial in patients with wet age-related macular degeneration (AMD) at the 47th Annual Meeting of the Macula Society. Wet AMD is a leading cause of blindness in people over the age of 65, requiring life-long anti-VEGF injections.

Adverum Biotechnologies - Prism MarketView

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. I

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD - Prism MarketView

Adverum Biotechnologies, Inc.– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both...

“Our goal with Ixo-vec is to provide patients virtually injection-free management of their wet AMD lasting years and potentially for life. We are pleased with the emerging treatment profile of Ixo-vec, showing potential for best-in-class efficacy and over 90% of subjects having no or minimal inflammation with our go-forward local prophylactic regimen. We are proud to build upon our pioneering efforts with the most mature dataset and longest follow-up of all wet AMD intravitreal gene therapies currently in development.”

Laurent Fischer, M.D., President and Chief Executive Officer of Adverum Biotechnologies

Highlights

The LUNA trial is an ongoing double-masked, randomized, Phase 2 trial of 60 patients with wet AMD.

Ixo-vec is a non-surgical treatment administered as a one-time IVT injection in the physician’s office, delivering long-term efficacy, optimizing patient compliance and improving vision outcomes for patients with wet AMD.

Ixo-vec has been granted FDA Fast Track designation, PRIME designation from the EMA and the Innovation Passport from the UK’s Medicines and Healthcare Products Regulatory Agency for the treatment of wet AMD.

Wet AMD affects approximately 10% of patients living with AMD and approximately 20 million individuals worldwide.

AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.